No-progression (n = 86) | Progression (n = 26) | p | |
---|---|---|---|
Age (yr) | 69.00 (61.00–76.00) | 70.50 (63.75–78.00) | 0.370b |
BMI (kg/m2) | 23.0 (21.2–26.3) | 24.6 (22.3–27.0) | 0.100b |
ORC | 65 (75.6%) | 19 (73.1%) | 0.796c |
LRC | 21 (24.4%) | 7 (26.9%) | |
Location of the tumor | 0.777c | ||
Posterior wall or trigone | 62 (72.1%) | 18 (69.2%) | |
Other location | 24 (27.9%) | 8 (30.8%) | |
Pathologic stage | 0.159c | ||
Ta and Tis and T1 | 25 (29.1%) | 3 (11.5%) | |
T2 | 31 (36.0%) | 10 (38.5%) | |
T3 and T4 | 30 (34.9%) | 13 (50.0%) | |
Pathologic nodal stage | 0.006c | ||
N0 | 79 (91.9%) | 18 (69.2%) | |
N+ | 7 (8.1%) | 8 (30.8%) | |
Negative margin | 83 (96.5%) | 24 (92.3%) | 0.329c |
Positive margin | 3 (3.5%) | 2 (7.7%) | |
No neoadjuvant/adjuvant chemotherapy | 79 (91.9%) | 17 (65.4%) | 0.002c |
Neoadjuvant/adjuvant chemotherapy | 7 (8.1%) | 9 (34.6%) |